S&P Futures
5,968.50 +10.25 (+0.17%) Dow Futures
44,011.00 +110.00 (+0.25%) Nasdaq Futures
20,934.25 +40.25 (+0.19%) Russell 2000 Futures
2,412.30 +6.50 (+0.27%) Crude Oil
72.04 +0.35 (+0.49%) Gold
2,665.50 -10.80 (-0.40%)
Cognition Therapeutics, Inc. (CGTX)
After hours:
| Previous Close | 0.4882 |
| Open | 0.5145 |
| Bid | 0.5003 x 100 |
| Ask | 0.5054 x 100 |
| Day's Range | 0.4901 - 0.5200 |
| 52 Week Range | 0.3400 - 2.9500 |
| Volume | |
| Avg. Volume | 561,023 |
| Market Cap | 20.058M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.20 |
GlobeNewswireCognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD)
GlobeNewswireCognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Thera
